Biological Description

Specificity Phospho-Rad17 (Ser645) Antibody [D14D16] detects endogenous levels of total Rad17 protein only when it is phosphorylated at Ser645.
Background Phospho-Rad17 at Ser645 represents the activated form of the Rad17 checkpoint protein within the RFC-like clamp loader family, critical for sensing DNA damage and replication stress to enforce cell cycle arrest. The protein maintains a toroidal structure analogous to replication factor C, with distinct AAA+ ATPase domains that facilitate interaction with the Rad9-Rad1-Hus1 (9-1-1) sliding clamp and recruitment to chromatin at ssDNA-dsDNA junctions via ATRIP-RPA recognition. Upon genotoxic insult from ionizing radiation or replication inhibitors, ATR kinase targets the SQ motif at Ser645 for phosphorylation through a two-step process where pre-bound Rad17 captures the 9-1-1 complex, amplifying local ATR activity and enabling phospho-Ser645-dependent conformational shifts that stabilize clamp loading and propagate downstream signaling. This modification licenses Rad17 to scaffold the MRN complex (MRE11-RAD50-NBS1) at double-strand breaks, channeling ATM/ATR activation toward CHK1/CHK2 phosphorylation cascades that halt S-phase progression and G2/M transition via Cdc25 inactivation. Phospho-Ser645 peaks in late G1 through G2/M during unperturbed replication but surges rapidly in early G1 under damage, reflecting cell cycle-regulated basal priming overlaid with inducible ATR/ATM responses. Mutation to alanine at Ser645 alongside Ser635 abolishes G1/S and G2 checkpoint enforcement, rendering cells hypersensitive to clastogens and replication toxins. ATM-deficient contexts sustain Ser645 phosphorylation albeit suboptimally, underscoring ATR dominance in this event.

Usage Information

Application WB, IP Dilution
WB IP
1:1000 1:200
Reactivity Human
Source Rabbit Monoclonal Antibody MW 80 kDa
Storage Buffer PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
Storage
(from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

References

  • https://pubmed.ncbi.nlm.nih.gov/11687627/
  • https://pubmed.ncbi.nlm.nih.gov/11418864/

Application Data

WB

Validated by Selleck

  • F6403-wb
    Lane 1: Hela, Lane 2: Hela (CIP and λ phosphatase treated)